Needle Shield Removal Assembly, Method for Assembling Thereof and Drug Delivery Device
20230347071 · 2023-11-02
Inventors
- Uwe Dasbach (Frankfurt am Main, DE)
- Robin Einwächter (Frankfurt am Main, DE)
- Phillip Hintermeier (Frankfurt am Main, DE)
- Ulrik Michael Jakobi (Frankfurt am Main, DE)
- Ngoc Jane Lam (Frankfurt am Main, DE)
- Raik Reimer (Frankfurt am Main, DE)
Cpc classification
A61M5/2033
HUMAN NECESSITIES
A61M5/3213
HUMAN NECESSITIES
International classification
A61M5/32
HUMAN NECESSITIES
Abstract
A needle shield removal assembly includes a needle shield gripper configured to operatively engage a needle shield, and a gripper holder, wherein the needle shield gripper is secured to the gripper holder via a connection interface, wherein the connection interface is formed by a holder interface feature engaging a gripper interface feature, wherein the gripper holder has an opening configured to receive the needle shield gripper and/or the needle shield, wherein the holder interface feature is offset from the opening, wherein the gripper holder defines a receiving space within which the needle shield gripper is received, wherein the receiving space has an axial extension, and wherein the needle shield gripper and the gripper holder are adjusted to one another to reduce mechanical contact of a) the gripper holder and a bent region of the needle shield gripper and/or b) the gripper holder and an edge of the needle shield gripper.
Claims
1-41. (canceled)
42. A needle shield removal assembly for a drug delivery device, the needle shield removal assembly comprising: a needle shield gripper configured to operatively engage a needle shield and to interlock with the needle shield; and a gripper holder, wherein the needle shield gripper is secured to the gripper holder via a connection interface established between the gripper holder and the needle shield gripper, wherein the connection interface is formed by at least one holder interface feature of the gripper holder engaging at least one gripper interface feature of the needle shield gripper; wherein the gripper holder has a holder opening, the holder opening being configured and dimensioned to receive the needle shield gripper and/or the needle shield, wherein the at least one holder interface feature is offset from the holder opening; wherein the gripper holder defines a receiving space within which the needle shield gripper is received; wherein the receiving space has an axial extension directed away from the holder opening; and wherein the gripper holder has a radial recess or a radial opening in a section of the gripper holder which is axially and/or angularly offset from the at least one holder interface feature.
43. The needle shield removal assembly of claim 42, wherein the receiving space is delimited by a portion of the gripper holder, and wherein the portion of the gripper holder comprises a section with a cylindrical surface provided between the holder opening and the holder interface feature.
44. The needle shield removal assembly of claim 43, wherein the portion of the gripper holder is radially inwardly offset from an inner surface of the gripper holder.
45. The needle shield removal assembly of claim 42, wherein the radial recess or radial opening is connected to the receiving space and extends outwardly as seen from the receiving space into or through the gripper holder or a portion thereof.
46. The needle shield removal assembly of claim 42, wherein the at least one holder interface feature protrudes into the receiving space.
47. The needle shield removal assembly of claim 42, wherein the gripper holder is a unitary component.
48. The needle shield removal assembly of claim 42, wherein an angular width of the radial recess or radial opening varies as seen along an axial extension of the radial recess or radial opening.
49. The needle shield removal assembly of claim 42, wherein a first axial end of the radial recess or radial opening which faces towards the holder opening is axially offset from the holder opening, and wherein a second axial end of the radial recess or radial opening is axially offset from the at least one holder interface feature in a direction away from the holder opening.
50. The needle shield removal assembly of claim 49, wherein the second axial end of the radial recess or radial opening which is remote from the first axial end is an open axial end, or wherein the first axial end of the radial recess or the radial opening is associated with an axial position of the holder interface feature, or wherein the first axial end of the radial recess or radial opening is arranged closer to the holder opening than an end of the at least one holder interface feature facing towards the holder opening, or wherein the first axial end of the radial recess or radial opening and an end of the at least one holder interface feature facing towards the holder opening are axially aligned.
51. The needle shield removal assembly of claim 42, wherein the at least one holder interface feature comprises an inclined region at an end of the holder interface feature facing towards the holder opening.
52. The needle shield removal assembly of claim 42, wherein the needle shield gripper comprises at least one kinked or bent region which overlaps with the radial opening or radial recess as seen in the angular direction.
53. The needle shield removal assembly of claim 52, wherein an angular width of the radial recess or radial opening is greater than an angular width of the kinked or bent region of the needle shield gripper.
54. The needle shield removal assembly of claim 42, wherein the holder interface feature is arranged to block movement of the needle shield gripper towards the holder opening by a blocking portion of the needle shield gripper abutting a surface of the holder interface feature facing away from the opening.
55. The needle shield removal assembly of claim 54, wherein the blocking portion of the needle shield gripper is arranged in a region between an end surface of the needle shield gripper and an axially oriented portion of the needle shield gripper, or wherein the blocking portion is arranged in a region of a tab or tongue of the gripper holder, or wherein the end surface faces in the radial inward direction, or wherein the end surface is a surface defined by cutting or punching.
56. The needle shield removal assembly of claim 54, wherein the blocking portion is arranged in a transition region of the needle shield gripper, or wherein, in the transition region, the needle shield gripper changes the orientation from a predominantly axial orientation to a predominantly radial orientation, or wherein the needle shield gripper is concavely curved in the region of the blocking portion or a region adjacent to the blocking portion, or wherein the gripper interface feature is an opening delimited axially by the blocking portion, or wherein the needle shield gripper has at least one needle shield interlock feature, the needle shield interlock feature being adapted to interlock with the needle shield, wherein a) the blocking portion is angularly aligned with one of the needle shield interlock features and/or b) the needle shield interlock feature protrudes radially beyond the end surface.
57. The needle shield removal assembly of claim 42, wherein the needle shield gripper is elastically deformable in the radial direction, or wherein the needle shield gripper comprises an oblique surface region which is arranged at an axial position offset from the holder interface feature in a direction away from the opening, and wherein the oblique surface region angularly overlaps with the at least one holder interface feature, or wherein the needle shield gripper has a plurality of needle shield interlock features, each of the plurality of needle shield interlock features being adapted to interlock with the needle shield, wherein the at least one holder interface feature is angularly aligned with one of the plurality of needle shield interlock features.
58. The needle shield removal assembly of claim 42, wherein the gripper holder comprises a radially extending recess or a radial opening in a sensitive region to prevent or reduce mechanical contact with the needle shield gripper in the sensitive region, or wherein the needle shield gripper comprises a plurality of bent or kinked regions, wherein a plane surface region or a less bent surface region of the needle shield gripper is arranged between two adjacent bent or kinked regions, and wherein the at least one sensitive region is arranged angularly between two adjacent bent or kinked regions.
59. A drug delivery device comprising the needle shield removal assembly of claim 42 and a reservoir, the reservoir comprising a drug, wherein the drug delivery device further comprises a needle and a needle shield, the needle being at least partly covered by the needle shield, wherein the needle shield gripper engages the needle shield such that the needle shield can be removed from the needle using the needle shield removal assembly, and wherein the needle shield removal assembly is a cap assembly of the drug delivery device.
60. A needle shield removal assembly for a drug delivery device, the needle shield removal assembly comprising: a needle shield gripper configured to operatively engage a needle shield and to interlock with the needle shield; and a gripper holder, wherein the needle shield gripper is secured to the gripper holder via a connection interface established between the gripper holder and the needle shield gripper, wherein the connection interface is formed by at least one holder interface feature of the gripper holder engaging at least one gripper interface feature of the needle shield gripper; wherein the gripper holder has a holder opening, the holder opening being configured and dimensioned to receive the needle shield gripper and/or the needle shield; wherein the holder interface feature is arranged to block movement of the needle shield gripper towards the holder opening by a blocking portion of the needle shield gripper abutting a surface of the holder interface feature facing away from the opening; and wherein the blocking portion of the needle shield gripper is arranged in a region between an end surface of the needle shield gripper and an axially oriented portion of the needle shield gripper.
61. A needle shield removal assembly for a drug delivery device, the needle shield removal assembly comprising: a needle shield gripper configured to operatively engage a needle shield and to interlock with the needle shield; and a gripper holder, wherein the needle shield gripper is secured to the gripper holder via a connection interface established between the gripper holder and the needle shield gripper, wherein the connection interface is formed by at least one holder interface feature of the gripper holder engaging at least one gripper interface feature of the needle shield gripper; wherein the gripper holder has an opening, the opening being configured and dimensioned to receive the needle shield gripper and/or the needle shield, wherein the at least one holder interface feature is offset from the opening; wherein the gripper holder defines a receiving space within which the needle shield gripper is received, wherein the receiving space has an axial extension directed away from the opening; and wherein the needle shield gripper and the gripper holder are adjusted to one another to reduce or prevent mechanical contact of a) the gripper holder and a bent or kinked region of the needle shield gripper and/or of b) the gripper holder and an edge or corner of the needle shield gripper during insertion of the needle shield gripper into the receiving space via the opening in at least one sensitive region of the gripper holder which is angularly offset from the at least one holder interface feature.
Description
BRIEF DESCRIPTION OF THE FIGURES
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
DETAILED DESCRIPTION
[0166] In the drawings, identical elements, elements of the same kind and identically acting elements may be provided with the same reference numerals.
[0167]
[0168] The autoinjector 1 includes a housing 2. The housing includes a front part 2.1, e.g., sleeve shaped, and a rear part 2.2. The front and rear part are preferably secured to one another, e.g., irreleasably. Alternatively, the housing 2 may be formed as a one-piece housing (not shown).
[0169] The housing 2 is adapted to hold a reservoir, in particular a syringe 3, e.g., a glass syringe. The syringe 3 may be a pre-filled syringe containing a liquid medicament M. The syringe may have a needle 4 arranged at a distal end. In another exemplary embodiment, the syringe 3 may be a cartridge which includes the medicament M and engages a removable needle (e.g., by threads, snaps, friction, etc.). Alternatively, the cartridge may be brought into engagement with the needle during an injection operation. In the shown exemplary embodiment, the syringe 3 is held in the housing 2. The syringe 3 is supported, preferably at its proximal end, in the housing by a syringe support 15. Preferably, the syringe and/or the needle are stationary during the operation of the autoinjector. Although the embodiments are directed to autoinjectors the disclosed concepts relating to the needle shield removal may also apply to other types of delivery devices, i.e., non-autoinjectors.
[0170] The autoinjector 1 further includes a protective needle shield 5 that is coupled to the needle 4. For example, the protective needle shield 5 is removably coupled to the needle 4. The protective needle shield 5 may be a rubber needle shield (often termed: soft needle shield or SNS) or a rigid needle shield (in short: RNS) which is composed of rubber and/or a full or partial plastic shell. The needle shield 5 may engage the syringe and/or the needle. The needle shield may cover a tip of the needle.
[0171] A stopper 6 is arranged or provided for sealing the syringe 3 in a proximal direction P and for displacing the medicament M contained in the syringe 3 through the needle 4. That is to say, if the stopper is displaced distally relative to the syringe, medicament may be dispensed from the syringe. The stopper may seal the interior of the syringe proximally.
[0172] The terms “drug” or “medicament” are used synonymously herein and describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharmaceutically acceptable salts or solvates thereof, and optionally a pharmaceutically acceptable carrier. An active pharmaceutical ingredient (“API”), in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.
[0173] As described below, a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more diseases. Examples of API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
[0174] The drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs. For example, in some instances, the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20° C.), or refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be-administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and/or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
[0175] The drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and/or prophylaxis of many different types of medical disorders. Examples of disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis. Examples of APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15th edition.
[0176] Examples of APIs for the treatment and/or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms “analogue” and “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring peptide and/or by adding at least one amino acid residue. The added and/or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogues are also referred to as “insulin receptor ligands”. In particular, the term “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g. a fatty acid) is bound to one or more of the amino acids. Optionally, one or more amino acids occurring in the naturally occurring peptide may have been deleted and/or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable, have been added to the naturally occurring peptide.
[0177] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
[0178] Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
[0179] Examples of GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide (Lyxumia®), Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Victoza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.
[0180] An examples of an oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.
[0181] Examples of DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
[0182] Examples of hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
[0183] Examples of polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.
[0184] The term “antibody”, as used herein, refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab′)2 fragments, which retain the ability to bind antigen. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region. The term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and/or a dual variable region antibody-like binding protein having cross-over binding region orientation (CODV).
[0185] The terms “fragment” or “antibody fragment” refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab′)2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
[0186] The terms “Complementarity-determining region” or “CDR” refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term “framework region” refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
[0187] Examples of antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).
[0188] Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device. Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
[0189] Those of skill in the art will understand that modifications (additions and/or removals) of various components of the APIs, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the present invention, which encompass such modifications and any and all equivalents thereof.
[0190] The autoinjector 1 further includes a, e.g., sleeve-shaped, needle shroud 7. In an exemplary embodiment, the needle shroud 7 is telescopically coupled to the housing 2 and movable between an extended position relative to the housing 2 in which the needle 4 is covered and a retracted position relative to the housing 2 in which the needle 4 is exposed. Furthermore, a shroud spring 8 is arranged to bias the needle shroud 7 in a distal direction D with respect to the housing 2. Thus, the position in which the needle is covered may be the standard position of the needle shroud defined by the shroud spring.
[0191] A drive spring 9, e.g., in the shape of a, preferably helical, compression spring, is arranged within the housing 2, e.g., in a proximal part thereof, in particular the rear part 2.2. A plunger 10 serves for forwarding the force of the drive spring 9 to the stopper 6. In an exemplary embodiment, the plunger 10 is hollow and the drive spring 9 is arranged within the plunger 10, biasing the plunger 10 in the distal direction D against the rear part 2.2. In another exemplary embodiment, the plunger 10 may be a solid piece without a hollow and the drive spring 9 may engage a proximal end of the plunger 10. Likewise, the drive spring 9 could be wrapped around the outer diameter of the plunger 10 and/or extend into the syringe 3.
[0192] The autoninjector 1 further includes a plunger release mechanism 12. The plunger release mechanism 12 is arranged for preventing release of the plunger 10 prior to depression of the needle shroud 7 and for releasing the plunger 10 once the needle shroud 7 is sufficiently depressed. The plunger may be arranged to displace the stopper 6 during operation in order to eject or dispense medicament from the syringe 3. The needle shroud may therefore act as a trigger member which is moved to trigger an injection operation.
[0193] In an exemplary embodiment, the autoinjector 1 further includes at least one audible indicator 13 for producing an audible feedback for a user or patient indicating that medicament delivery is complete. In other words: The audible indicator 13 is adapted to indicate to a user or a patient that the full dose of medicament M was delivered. The audible indicator 13 is formed for example as a bistable spring and is held in the rear part 2.2.
[0194] To allow an accurate support of the syringe 3 during and/or after assembly, the autoinjector 1 includes a carrier 16 adapted to mount and hold the syringe 3 within the housing 2, e.g., in a forward or distal direction D. Due to manufacturing tolerances, syringes 3 may have variable lengths. Thus, a flange 3.1 of the syringe 3 protrudes from the carrier 16 in the proximal direction P. To support the axial position of the syringe 3 relative to the housing 2 after assembly, in particular during storage, transportation and normal use, the syringe support 15 includes one or more supporting beams 15.1 extend radially inwards or longitudinally to accommodate the variable length of the syringe 3 in an assembled state. The supporting beams 15.1 are adapted to axially bias the syringe 3 in the distal direction D within the housing 2 and to compensate the variable length of the syringe 3 in the distal direction D.
[0195] Furthermore, the autoinjector 1 includes a cap 11 that may be removably disposed at a distal end of the housing 2, in particular at a distal end of the front part 2.1. The cap 11 may be releasably connected to the housing, e.g., by a snap-fit or a threaded connection. The cap 11 may include outer grip features 11.1 for facilitating removal of the cap 11, e.g., by twisting and/or pulling the cap 11 off the housing 2. The cap 11 may further include a gripper 11.2 arranged to engage and grip the protective needle shield 5. The gripper 11.2 forms an inner grip element and is fixed to the cap 11. The cap 11 may be of plastic. The gripper 11.2 may be of metal.
[0196] The cap 11 is adapted to form part of a needle shield remover or removal assembly. For this purpose, the cap 11 and the gripper 11.2 are connected in such a manner that removal of the cap 11 together with the fixed gripper 11.2 from the autoinjector 1 removes the protective needle shield 5 from the needle 4. In other words: The gripper 11.2 is coupled to the cap 11 in a manner such that, when the cap 11 is removed, the protective needle shield 5 is also removed from the needle 4. Therefore, the cap assembly including the cap and the gripper secured to it is a needle shield removal assembly. The cap 11 acts as gripper holder.
[0197] Furthermore, a shroud pre-lock mechanism 14 is provided which is arranged and/or configured to prevent depression of the needle shroud 7 when the cap 11 is in place, thus avoiding unintentional activation of the autoinjector 1, e.g., if dropped, during shipping or packaging, etc.
[0198]
[0199] The gripper 11.2 includes at least a gripper carrier or main body 11.3. The gripper carrier 11.3 is multiply bent or kinked along a plurality of longitudinal fold edges, kinks or bends 11.4 to form a plurality of carrier portions 11.5. The respective carrier portions may have or include a plan outer surface region. Furthermore, the gripper carrier 11.3 is bent or angled in such a manner that the outer carrier portions 11.5 are partly overlapping in an overlapping area 11.6. Hence, in the bent state the gripper carrier 11.3 has a pipe-form or tube-form with a polygonal cross section. The partly overlapping area 11.6 in the bent state of the gripper carrier 11.3 allows compensation of manufacturing tolerances of the gripper 11.2. The gripper carrier has free ends which may be arranged closed to the overlapping area 11.6
[0200] To grip the protective needle shield 5, more than one of the plurality of carrier portions 11.5 includes a cut-out or opening 11.7 from which a respective barb 11.8 is bent and projected inwards from the inner surface of the gripper carrier 11.3 and thus of the carrier portions 11.5. In the assembled state, the inwardly angled barbs 11.8 extend in the distal direction D of the autoinjector 1.
[0201] In the context of the present disclosure, “proximal” is used to designate a position which is further away or a direction pointing away from a dispensing end or an application site of the device or component of the device under consideration. “Distal” is used to designate a position which is closer to or a direction pointing towards a dispensing end or an application site of the device or component of the device under consideration
[0202] The barbs 11.8 are adapted to deflect and grip the protective needle shield 5 during assembly of the needle shield 5 into the autoinjector 1 and are adapted to further grip the needle shield 5 when the cap 11 is being removed from the autoinjector 1.
[0203] The barbs 11.8 are designed as hooks or have a prong-form. In particular, the barbs 11.8 are inwardly projected from the inner surface of the carrier portions 11.5 and include on its free end prongs 11.9. The prongs 11.9 are adapted to press onto or dig into the outer surface of the protective needle shield 5 and to form an interference fit during assembling or a positive and/or non-positive connection at least during removing of the protective needle shield 5. According to another aspect, the prongs 11.9 may be adapted to already dig into the outer surface of the protective needle shield 5 when the gripper 11.2 is being assembled to the protective needle shield 5 as described above. That is to say, a form-fit or positive fit may already be applied during the assembling process and not just after commencement of the cap removal process.
[0204] According to the present embodiment, the prongs 11.9 are configured as double spikes respectively arranged on each barb 11.8. This configuration is realized by a concave shape respectively between two prongs 11.9 per barb 11.8. Due to the concave shape and thus controlling the distance between the prongs 11.9, a penetration depth into the surface of the protective needle shield 5 may be limited. This is particularly important, when the needle shield is a rubber needle shield where penetration beyond a certain limit could impact sterility by accessing the needle 4.
[0205] Furthermore, for correct orientation of the gripper 11.2 during assembling within the cap 11, the gripper 11.2 includes an orientation element 11.10 indicating an assembling orientation. The orientation element 11.10 is designed as a tactile indicator or visual indicator or a combination of them. In particular, one of the front surfaces of the gripper carrier 11.3 is profiled, e.g., waved or pronged, and the other opposite front surface is even and flat. The orientation feature may be a cutout.
[0206]
[0211] The sheet 11.11 may be a single piece of sheet metal which is cut, e.g., by punching or stamping, to form the cut-outs or openings 11.7 and barbs 11.8 in the cut-outs or openings 11.7.
[0212] To retain the gripper 11.2 within the cap 11, the sheet 11.11 includes at least one retaining slot 11.12, which may be formed by cutting or punching into the gripper carrier 11.3. In the present embodiment, for example two retaining slots 11.12 are provided. The retaining slots 11.12 serve for retaining the gripper 11.2 within the cap 11, e.g., by holding lugs 11.13 of the cap 11 shown in
[0213] In an alternative embodiment, for retaining the gripper 11.2 within the cap 11, the gripper carrier 11.3 may include retaining lugs 11.14 (dotted line) and the cap 11 may include holding slots (not shown). In this case, the optional retaining lugs 11.14 and the barbs 11.8 of the gripper 11.2 are radially bent in opposite directions from the gripper carrier 11.3. In particular, the gripper carrier 11.3 is formed as an anchoring part or main part including the plurality of barbs 11.8 or claws inwardly directed away from the gripper carrier 11.3 and at an angle in the direction to a longitudinal axis A of the gripper 11.2 and bearing against the outer surface of the needle shield to grip the needle shield 5 wherein the retaining lugs 11.14 are outwardly bent and oriented at an angle away from the axis A and bearing against the inner cap surface of the cap 11 to grip the cap 11.
[0214]
[0215]
[0216] As an alternative to the interference fit of the barbs 11.8 and the needle shield 5, the barbs 11.8 may be dug into the outer surface of the needle shield 5 to form a mechanical locking connection, e.g., a force-locking connection, form-fitting connection and/or friction-locking connection by interlocking structures, hooks and eyes or protrusions and undercuts, profiled surfaces, etc., at least during removing of the protective needle shield 5.
[0217] In an embodiment, the needle shield gripper 11.2 has at least one outer edge and/or inner edge which is defined by punching or cutting. Preferably, all outer edges and/or all inner edges of the needle shield gripper are defined by punching or cutting. This enables to form the needle shield gripper in a defined manufacturing step without significant subsequent modification steps to the part which has been manufactured, e.g., by punching. The part may be bent into the desired shape after punching or cutting as discussed for the metal sheet above. The manufacturing method, e.g., punching, may, however, generate sharp edges of the gripper as may the subsequent bending, wherein in the bent or kinked regions which are generated by bending, the effect is particularly pronounced, as in bent or kinked regions, the radius of curvature is particularly small with associated forces being particularly high when these regions—either the side faces defined by these regions or the corners at the ends of these regions—contact the wall of the cap/gripper holder.
[0218]
[0219] The interface features 11.13 have, on the side facing the opening 11.16, a sloped section and on the side facing away from the opening a less sloped section, which, preferably, is more radially oriented than the sloped section. This facilitates advancing of the gripper 11.2 during assembly of the gripper 11.2 into the receiving space 11.15 with an associated elastic deformation in the radial direction. The gripper 11.2 may be elastically deformed already when it engages the section of the cap between the opening 11.16 and the interface features 11.13. When the gripper interface feature has passed the holder interface feature 11.13, it is securely retained in the receiving space 11.15 due to the radially oriented surface of the feature 11.13 preventing removal of the gripper 11.2.
[0220]
[0221] The gripper 11.2 has two opposite axial ends, the first or leading end 11.20 and the second or trailing end 11.21. The first end 11.20 is the one which is firstly introduced into the opening 11.15 during the assembling process. The gripper 11.2 has an oblique surface region 11.22 disposed at the leading end 11.20. The region 11.22 is inclined and directed away from the axis as seen from the first end 11.20. The region 11.22 may be designed to interact with the holder interface feature 11.13 which should engage the associated gripper interface feature 11.12. The oblique surface region 11.22 is aligned with the gripper interface feature 11.12 and/or the holder interface feature 11.13 which it should engage when it is assembled to the cap 11 angularly. Axially the oblique surface region 11.22 is offset from the gripper interface feature 11.12, which is may be formed by the opening 11.7 in the embodiment depicted in
[0222] In
[0223] Accordingly, at the leading end or leading edge, the kinks or bends 11.4 may define corners 11.25. The respective corner may be an angled region of the edge of the gripper 11.2. The edge or corner 11.25 may be oriented in the axial direction, i.e. face away from the opening 11.16. When guiding the gripper 11.2 depicted in
[0224] When investigating scraping or flake generation, it has been found that some regions are particularly sensitive for generating scrapes of flakes. These regions are interior regions of the cap and, in particular of the portion 11.17. Surprisingly, it has been found that regions which are angularly offset from the interface features 11.13, e.g. by 90° in case two interface features 11.13 are provided, are particularly sensitive as regards the generation of flakes or scrapes. One particular sensitive region was the one angularly aligned with the gripper guide feature 11.19, which may be angularly offset from the holder interface feature(s), e.g., by 90°. Alternatively or additionally, the region distally offset from the interface features 11.13 was particularly susceptible for damages of the cap caused by the gripper.
[0225] The presence of these regions may be due to the elastic deformation of the gripper 11.2 during the assembling process. Here, the gripper is at first is slightly elastically deformed, e.g., on account of the opening having a smaller diameter than the non-deformed gripper 11.2, before the gripper 11.2 engages the interface features 11.13. Then, the radial elastic deformation is increased. Accordingly, there may be considerably forces acting in the radial direction and those forces may tend to enlarge the diameter of the gripper in one or more regions which are angularly offset from the holder interface features 11.13. The scraping or flake generation was particularly pronounced when a bent or kinked region 11.4 and/or the associated corner 11.25 was arranged in the sensitive region.
[0226]
[0227] The scraping or flake generation may be due to sharp edges formed during the manufacturing of the gripper 11.2, e.g., by punching or another process described previously, and/or by small radii of curvature in the kinked or bent region which are formed when bending the sheet to form the gripper 11.2.
[0228] In the following, some concepts are proposed which are suitable to reduce or prevent the scraping or flake generation in the gripper holder/cap 11, particularly in the sensitive region(s) thereof when assembling the gripper 11.2 to the cap 11.
[0229]
[0230] The protrusions 11.26 may be formed by deep-drawing or embossing and can, therefore, be easily integrated into the manufacturing process of the gripper 11.2 as these methods are suitable methods for shaping metal parts or sheets.
[0231] In the region of the orientation feature 11.10, it is particularly advantageous, when the gripper 11.2 contacts the cap 11, as, otherwise, the mechanical cooperation with the gripper guide feature 11.19 might not be achieved. Lacking cooperation would impede the guiding functionality and increase the likeliness of not assembling the cap and the gripper properly, i.e., such that the connection interface between the interface features 11.12 and 11.13 is established. Consequently, in the region of the guide feature 11.10, it is particularly likely that scrapes or flakes occur. The protrusions may protrude by about 0.45 mm from the surface of the gripper 11.2. The protrusion may have a closed circumferential edge, e.g., a circular edge, on the outer surface of the gripper 11.2. The protrusions may have a general semi-spherical shape. The respective protrusion 11.26 may be confined to one surface of the gripper 11.2, e.g., the side surface. That is to say, when seen in top view onto the surface of the gripper, the respective protrusion 11.26 may be confined to that surface, preferably confined to one of the portions 11.5. As seen in top view onto a free end of the protrusion, the respective protrusion may have a circular or oval shape.
[0232] Moreover, as has been explained above, the orientation element or feature 11.10 is angularly offset from the holder interface feature 11.13 and/or the gripper interface feature 11.12 engaging the holder interface feature. This arrangement makes it likely that, due to elastic deformation, high contact forces between the gripper 11.2 and the gripper holder/cap 11 occur in this region. The protrusions 11.26 may be generated by embossing using a ball punch, e.g., a 2.0 millimeters diameter ball punch. The (maximum) diameter of the protrusion as seen in top view onto the free end may be less than or equal to 2 mm. The protrusions may protrude by less than 1 mm, preferably less than 0.8 mm or less than 0.7 mm, e.g. less than or equal to 0.5 mm from the outer surface, e.g. by 0.45 mm+/−0.05 mm. Alternatively or additionally, the respective protrusion protrudes by 0.3 mm or more, from the outer surface of the gripper 11.2. Protrusions which elevate from the outer surface by the respective height have proven to be particularly advantageous. For protrusions with a smaller height, e.g. 0.25 mm, the generation of scrapes or flakes was observed to occur with an increased likelihood. The protrusions 11.26 may be arranged such that they protrude radially beyond the bent or kinked region 11.4 arranged angularly between the protrusions 11.26 and/or beyond the corner 11.25 arranged angularly between the protrusions 11.26. Particularly, an enveloping curve, e.g., a circle, which runs through the free ends of the protrusions 11.26 may have a radial distance to the corner 11.25 and/or the bent or kinked region 11.4. In this way, the protrusions 11.26 may maintain a distance between the outer surface of the gripper 11.2 and the inner surface of the cap, particularly in that regions, where it matters the most, i.e., the sensitive region. In the depicted embodiment only two protrusions are provided which are associated with one bent or kinked region 11.4. However, it should be appreciated that more protrusions could be provided. Also, one or more protrusions could also be associated with different bent or kinked regions or corners. Although an arrangement with the bent or kinked region 11.4 angularly between two protrusions 11.26 may be advantageous, the arrangement of the protrusions is not restricted to such an arrangement. Likewise, the protrusions do not have to be arranged symmetrically relative to the kinked or bent region 11.4 as depicted. Rather, two protrusions could be arranged on one side of the bent or kinked region 11.4. Also just one protrusion could be provided. Moreover the number of protrusions on one side of the bent or kinked region may be greater than or equal to the number of protrusions on the other side of that bent or kinked region 11.4.
[0233]
[0234] In this embodiment, protrusions 11.26 are used as well to reduce or prevent mechanical contact. However, the protrusions 11.26 are not provided on the gripper 11.2 as in the previous embodiment but rather on the cap 11, e.g., on an interior surface of the portion 11.17. The protrusions 11.26 are directed radially inward. The protrusions 11.26 are designed as longitudinally extending ribs. The protrusions may extend along the entire extension of the portion 11.17 of the cap. The axial extension of the protrusions/ribs may be greater than or equal to 70% of the axial extension of the gripper 11.2. A plurality of protrusions 11.26, e.g., four or more, may be distributed, e.g., evenly, in the circumferential or angular direction (see
[0235] In an embodiment, the distance, preferably measured in the angular direction, i.e., the angular distance, between the respective protrusion 11.26—the protrusion being provided on the gripper holder/cap or on the gripper—and the associated sensitive region, the associated bent or kinked region, and/or the associated edge or corner of the needle shield gripper is less than or equal to one of the following values: 2 mm, 1.5 mm, 1 mm, 0.7 mm, 0.6 mm, 0.5 mm. In case of doubt, the distance may be measured from the boundary of the protrusion closest to the bent or kinked region and/or the edge or corner along the surface of the element having the protrusion until the angular position of the boundary of the bent or kinked region and/or the edge or corner is reached.
[0236]
[0237] Although the distal end of the cap 11 is shown to be open in some of the figures, it may be closed, e.g., by an appropriate lid part assembled to the cap 11 or by a closure unitary with the remainder of the cap 11. However, an open distal end facilitates the illustration of the embodiments.
[0238]
[0239]
[0240]
[0241]
[0242] When the irregularly or rotationally asymmetrically shaped, e.g., oval, gripper 11.2 is inserted into the opening, it may still be elastically deformed by the contact with the wall delimiting the opening or the receiving space even before the interface features 11.13 engage with the outer surface of the gripper 11.2. However, the shape of the deformed gripper may still be such that the deformed gripper 11.2 has a distinct longitudinal axis and/or an oval enveloping curve as depicted in
[0243]
[0244]
[0245]
[0246] As depicted in
[0247] The holder interface features or lugs 11.13 of the cap 11 are engaged with the gripper interface features (retaining slot 11.12 and/or cutout or opening 11.7). As depicted, the gripper interface feature may be one of the cutouts or openings 11.7 which defines the gripper features 11.8, e.g., barbs, which are designed to interlock with the needle shield. As depicted in
[0248] As discussed already in conjunction with the embodiment depicted in
[0249] At least one edge, kink or bend 11.4 is arranged angularly in a position overlapping with the respective opening (see
[0250] The openings 11.27 have a first axial end 11.39. The first axial end 11.39 may delimit the respective opening axially on the side of the opening 11.27 facing towards the holder opening 11.16 and/or proximally. Preferably, the first axial end is offset from the end of the holder interface feature 11.13 facing towards the holder opening—e.g., the proximal end such as the proximal end of the inclined region 11.36—or arranged axially overlapping with the inclined region 11.36 of the holder interface feature. In other words, the axial onset of the opening 11.27 may be before the axial onset of the holder interface feature as seen from the holder opening 11.16 towards the holder interface feature 11.13 along axis A. The openings 11.27 reduce the impact or a mechanical load transferred from the gripper 11.2 to the cap 11, especially in a section where the gripper is axially deformed when the section of the gripper distal to the retention slot 11.12 interacts with the holder interface feature 11.13 as has been described already. The respective opening 11.27 may be open at the second axial end 11.46 which is remote from the first axial end 11.39. That is to say, the opening 11.27 may be accessible from the distal end of the cap. This is easily recognizable in
[0251] It should be noted, that, aside from having a radial opening which protrudes radially through the entire portion 11.17, a recess, which is radially outwards delimited by the portion 11.17, would also reduce the generation of scrapes of flakes in the cap 11 when assembling the cap 11 and the gripper 11.2. However, the opening may have advantages with respect to manufacturing.
[0252] The axial offset between the proximal end of the holder interface feature 11.13 and the first axial end 11.39 may be less than the axial extension of section 11.40. The axial offset between the first axial end and the holder interface feature may be less than or equal to 2 mm, e.g. 1.5 mm. The axial extension of the holder interface feature 11.13 may be 2 mm. As an alternative to a non-zero offset of the opening in the proximal direction relative to the holder interface feature, the first axial end 11.39 may be arranged at the same axial position as the proximal end of the holder interface feature or within the inclined region 11.36.
[0253] The angular width of the radial openings 11.27 may increase in the distal direction and/or in the direction away from the holder opening. The angular width, e.g., the minimum angular width of the respective radial opening or the maximum angular width of the respective radial opening, may be greater than or equal to the angular extension of one carrier portion 11.5 of the gripper 11.2, e.g., the smallest or the largest angular extension of the carrier portions 11.5, if the dimensions of the carrier portions 11.5 in the angular directions vary.
[0254] Surfaces delimiting the radial opening in the angular direction, such as surface 11.45 shown in
[0255] As depicted in
[0256] As depicted in
[0257]
[0258]
[0259] It should be noted that every gripper interface feature may be delimited axially by an according blocking portion.
[0260] Bending the tab or tongue may be comparatively easily implemented in the manufacturing process and does not require excessive adjustments such as new cutting or punching processes being established, for example.
[0261] In an embodiment of a method of assembling a needle shield gripper, a gripper structure may be formed, e.g., from a metal sheet. The gripper structure can be selectively deformed, e.g., bent, or treated in a region to form the blocking portion, e.g., the blocking portion which is specified further above. Forming the blocking portion may include deforming the region of the gripper structure such that a portion of the gripper structure including the end surface, e.g., the surface of end 11.48, is displaced out of a plane which is delimited by one, more, or all of the remaining boundary surfaces of a gripper structure opening in the gripper structure, where the end surface, before the portion was displaced, is arranged in the gripper structure opening, e.g., a sheet-like structure as depicted in
[0262] With a solution including the blocking portion, the risk of flake or scrape generation is further reduced which is why the according embodiment is particularly suitable, preferably, but not exclusively, in combination with the solutions discussed in
[0263] It should be noted that features which are disclosed above in conjunction with different aspects and embodiments can be combined with one another regardless of whether they are contained in the description of the exemplary embodiments or in the introductory or summary section of the present disclosure. Moreover, features, which are discussed only in the introductory section of the disclosure, should also be considered as being disclosed in the section discussing the exemplary embodiments and vice versa.
[0264] The scope of protection is not limited to the examples given herein above. Any invention disclosed herein is embodied in each novel characteristic and each combination of characteristics, which particularly includes every combination of any features, which are stated in the claims, even if this feature or this combination of features is not explicitly stated in the claims or in the examples.
REFERENCE NUMERALS
[0265] 1 autoinjector [0266] 2 housing [0267] 2.1 front part [0268] 2.2 rear part [0269] 2.4 proximal end [0270] 3 syringe [0271] 3.1 flange [0272] 4 needle [0273] 5 needle shield [0274] 6 stopper [0275] 7 needle shroud [0276] 8 shroud spring [0277] 9 drive spring [0278] 10 plunger [0279] 11 cap [0280] 11.1 grip feature [0281] 11.2 gripper [0282] 11.3 gripper carrier [0283] 11.4 longitudinal fold edges [0284] 11.5 carrier portion [0285] 11.6 overlapping area [0286] 11.7 cut-out/opening [0287] 11.8 barb [0288] 11.9 prong [0289] 11.10 orientation element [0290] 11.11 sheet [0291] 11.12 retaining slot [0292] 11.13 holding lug [0293] 11.14 retaining lug [0294] 11.15 receiving space [0295] 11.16 opening [0296] 11.17 portion [0297] 11.18 housing connector [0298] 11.19 gripper guide feature [0299] 11.20 first/leading end [0300] 11.21 second/trailing end [0301] 11.22 oblique surface region [0302] 11.23 surface [0303] 11.24 surface [0304] 11.25 edge/corner [0305] 11.26 protrusion [0306] 11.27 opening [0307] 11.28 tab [0308] 11.29 indentation [0309] 11.30 abutment feature [0310] 11.31 web [0311] 11.32 outer wall [0312] 11.33 grip features [0313] 11.34 lid [0314] 11.35 indicator [0315] 11.36 inclined region [0316] 11.37 surface [0317] 11.38 region [0318] 11.39 axial end [0319] 11.40 section [0320] 11.41 snap feature [0321] 11.42 snap feature [0322] 11.43 opening [0323] 11.44 surface [0324] 11.45 surface [0325] 11.46 axial end [0326] 11.47 tab or tongue [0327] 11.48 free end [0328] 11.49 axial portion [0329] 11.50 transition region [0330] 11.51 blocking portion [0331] 12 plunger release mechanism [0332] 13 audible indicator [0333] 14 shroud pre-lock mechanism [0334] 15 syringe support [0335] 15.1 supporting beam [0336] 16 carrier [0337] 17 scrape/flake [0338] A Longitudinal axis [0339] D distal direction [0340] G gap [0341] M medicament [0342] P proximal direction